ValuEngine lowered shares of Exelixis (NASDAQ:EXEL) from a hold rating to a sell rating in a research note issued to investors on Monday morning, ValuEngine reports.

Several other analysts have also recently commented on EXEL. Cowen upgraded Twitter from an underperform rating to a market perform rating in a report on Tuesday, April 23rd. Zacks Investment Research cut Great Portland Estates from a hold rating to a sell rating in a report on Tuesday, April 16th. Oppenheimer set a $13.00 target price on Alpine Immune Sciences and gave the stock a buy rating in a report on Tuesday, March 19th. Morgan Stanley increased their target price on Zynga and gave the stock an overweight rating in a report on Thursday, May 2nd. Finally, BidaskClub cut Wright Medical Group from a buy rating to a hold rating in a report on Thursday, May 23rd. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of Hold and an average price target of $28.88.

Shares of EXEL stock opened at $20.91 on Monday. The business’s fifty day simple moving average is $20.56. The company has a quick ratio of 7.48, a current ratio of 7.56 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $6.33 billion, a PE ratio of 14.62, a PEG ratio of 0.50 and a beta of 1.93. Exelixis has a 52 week low of $13.42 and a 52 week high of $25.31.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Wednesday, May 1st. The biotechnology company reported $0.24 EPS for the quarter, hitting the consensus estimate of $0.24. The company had revenue of $215.49 million for the quarter, compared to analysts’ expectations of $206.06 million. Exelixis had a return on equity of 37.21% and a net margin of 75.97%. The business’s revenue for the quarter was up .8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.40 earnings per share. Equities research analysts forecast that Exelixis will post 0.92 earnings per share for the current year.

In related news, CEO Michael Morrissey sold 34,721 shares of the firm’s stock in a transaction dated Wednesday, July 3rd. The stock was sold at an average price of $21.03, for a total value of $730,182.63. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director George A. Scangos sold 40,000 shares of the firm’s stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $19.84, for a total value of $793,600.00. Following the completion of the transaction, the director now owns 1,248,031 shares in the company, valued at approximately $24,760,935.04. The disclosure for this sale can be found here. In the last quarter, insiders sold 569,982 shares of company stock worth $11,691,192. 4.50% of the stock is owned by company insiders.

A number of institutional investors have recently bought and sold shares of EXEL. Icon Wealth Partners LLC bought a new position in Exelixis in the first quarter valued at about $27,000. JOYN Advisors Inc. boosted its holdings in Exelixis by 334.2% in the fourth quarter. JOYN Advisors Inc. now owns 1,524 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 1,173 shares during the last quarter. Cornerstone Advisors Inc. boosted its holdings in Exelixis by 26.5% in the first quarter. Cornerstone Advisors Inc. now owns 2,413 shares of the biotechnology company’s stock valued at $57,000 after acquiring an additional 505 shares during the last quarter. Rehmann Capital Advisory Group lifted its stake in Exelixis by 231.3% in the first quarter. Rehmann Capital Advisory Group now owns 2,438 shares of the biotechnology company’s stock valued at $58,000 after buying an additional 1,702 shares during the period. Finally, FinTrust Capital Advisors LLC lifted its stake in Exelixis by 124.0% in the first quarter. FinTrust Capital Advisors LLC now owns 2,533 shares of the biotechnology company’s stock valued at $61,000 after buying an additional 1,402 shares during the period. Institutional investors and hedge funds own 78.21% of the company’s stock.

About Exelixis

Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Recommended Story: Consumer behavior in bull markets

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.